MannKind Corporation Share Price Nasdaq
Equities
US56400P2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
08/05 | Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
08/05 | Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 | MT |
Sales 2024 * | 272M 22.73B | Sales 2025 * | 319M 26.59B | Capitalization | 1.2B 100B |
---|---|---|---|---|---|
Net income 2024 * | 35M 2.92B | Net income 2025 * | 70M 5.84B | EV / Sales 2024 * | 3.5 x |
Net cash position 2024 * | 248M 20.73B | Net cash position 2025 * | 273M 22.76B | EV / Sales 2025 * | 2.91 x |
P/E ratio 2024 * |
38.3
x | P/E ratio 2025 * |
20
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.48% |
Latest transcript on MannKind Corporation
Managers | Title | Age | Since |
---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 47 | 14/16/14 |
Sanjay Singh
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/22/01 |
Kevin Kaiserman
CTO | Chief Tech/Sci/R&D Officer | - | 31/20/31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 27/18/27 | |
Anthony Hooper
BRD | Director/Board Member | 69 | 01/20/01 |
Ronald Consiglio
BRD | Director/Board Member | 80 | 01/03/01 |
1st Jan change | Capi. | |
---|---|---|
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |